Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $46.59 and last traded at $43.82, with a volume of 233007 shares changing hands. The stock had previously closed at $45.67.
Gemini Therapeutics Price Performance
The business’s fifty day simple moving average is $41.42 and its two-hundred day simple moving average is $48.22. The company has a market cap of $1.90 billion, a PE ratio of -1.35 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- What Does Downgrade Mean in Investing?
- Survey: Top 175 Fittest Retirement Locations in America
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- Canadian Penny Stocks: Can They Make You Rich?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
